AACR19: MET inhibitor savolitinib shows promise for EGFR-mutant NSCLC
The addition of the investigational MET inhibitor savolitinib to the EGFR inhibitor osimerinib (Tagrisso®) is beneficial for certain pre-treated patients with EGFR-mutant non-small-cell lung cancer (NSCLC), according to results from the TATTON trial presented at the AACR Annual Meeting (March 29 – April 3, Atlanta, GA, USA).“Data from the TATTON trial demonstrate for the first time the benefit of adding a MET inhibitor to an EGFR inhibitor in patients with EGFR-mutant NSCLC and with MET-driven acquired resistance.”The results presented are interim data from two expansion cohorts of the Phase Ib trial, TATTON, demonstrating that there could be better treatment for...